Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019–2020)

References

• Wenzler E, Deraedt MF, Harrington AT, et al. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing Gram-negative pathogens. Diagn Microbiol Infect Dis. 2017;88(4):352–354.
   PubMed Web of Science ®Google Scholar
• Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(9):e01008–17.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544.
   PubMed Web of Science ®Google Scholar
• Biagi M, Wu T, Lee M, et al. Searching for the optimal treatment for metallo- and serine-β-Lactamase producing enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob Agents Chemother. 2019;63(12):e01426–19.
   PubMed Web of Science ®Google Scholar
• Maraki S, Mavromanolaki VE, Moraitis P, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755–1759.
   PubMed Web of Science ®Google Scholar
• Lee M, Abbey T, Biagi M, et al. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2021;99(1):115227.
   PubMed Web of Science ®Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(Suppl 7):S538–S543.
   PubMedGoogle Scholar
• Parsels KA, Mastro KA, Steele JM, et al. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections. J Antimicrob Chemother. 2021:1379-1391. doi: 10.1093/jac/dkab015.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 study). Int J Antimicrob Agents. 2019;53(2):177–184.
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-Negative bacteria, including Carbapenem-resistant nonfermenters and enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob Agents Chemother. 2019;63(1):e01801–18.
   PubMed Web of Science ®Google Scholar
• Delgado-Valverde M, Conejo MDC, Serrano L, et al. Activity of cefiderocol against high-risk clones of multidrug-resistant enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2020;75(7):1840–1849.
   PubMed Web of Science ®Google Scholar
• Dobias J, Dénervaud-Tendon V, Poirel L, et al. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36(12):2319–2327.
   PubMed Web of Science ®Google Scholar
• EUCAST clinical breakpoints cefiderocol addendum. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Addenda/Cefiderocol_addendum_20200501.pdf.
   Google Scholar
• Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52(12):4124–4128.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Karlowsky JA, de Jonge BLM, et al. Epidemiology of carbapenem resistance determinants identified in Meropenem-Nonsusceptible enterobacterales collected as part of a global surveillance program, 2012 to 2017. Antimicrob Agents Chemother. 2021;65(7):e0200020.
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Bochenska M, Fumagalli L, et al. Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008–2018. Diagn Microbiol Infect Dis. 2021;101(4):115512.
   PubMed Web of Science ®Google Scholar
• Bleibtreu A, Dortet L, Bonnin RA, on behalf of the Cefiderocol French Study Group, et al. Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study. Microorganisms. 2021;9(2):282.
   PubMed Web of Science ®Google Scholar
• Bianco G, Boattini M, Comini S, et al. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing enterobacterales: cross-resistance and synergistic effects. Eur J Clin Microbiol Infect Dis. 2022;41(1):63–70.
   PubMed Web of Science ®Google Scholar
• Simner PJ, Patel R. Cefiderocol antimicrobial susceptibility testing considerations: the achilles' heel of the trojan horse? J Clin Microbiol. 2020;59(1):e00951–20.
   PubMed Web of Science ®Google Scholar
• Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–S551.
   PubMedGoogle Scholar
• Iannaccone M, Boattini M, Bianco G, et al. Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2020;56(2):106066.
   PubMed Web of Science ®Google Scholar
• Mauri C, Maraolo AE, Di Bella S, et al. The revival of aztreonam in combination with avibactam against metallo-β-Lactamase-producing Gram-Negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021;10(8):1012.
   Google Scholar